Empliciti (elotuzumab) for the Treatment of Multiple Myeloma
Empliciti’s FDA approval was based on results from the ELOQUENT-2 Phase III clinical study. Image: courtesy of Bristol-Myers Squibb.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more